News Archive

Each spring Johns Hopkins honors exceptional graduate students and postdoctoral fellows at the annual Young Investigators’ Day celebration. The day is meant to celebrate the achievement and hard work of not only the award winners, but of all Johns Hopkins’ research trainees. This year two BME PhD candidates and a BME MD PhD candidate were selected to receive distinguished awards. The awards, named after notable researchers, including many who were former faculty members or graduate students at The Johns Hopkins University, were granted in recognition of outstanding research

You probably know Steve Case best as the man responsible for America Online. But two decades later, Case is continuing the charge to help the new generation of technology and business leaders define the critical path of Internet and innovation to become much more useful to society.

Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc’s Aricept® Tablets, 23mg.

Nearly 50 new medicines are projected to be launched each year by 2020, a new report from the IMS Institute for Healthcare Informatics says. As such, a number of new drug brands will be available on the market. The majority, unsurprisingly, will be designed to treat cancer.

At the MedCity INVEST conference this week, a panel made up of two CEOs who took their companies public and a couple of venture investors talked about the advantages and drawbacks of going public compared with a strategic acquisition. They also drew attention to what’s changing in the marketplace.

This ranking is based on eight metrics, organized into four categories: concentration, which is the number of software developers per 1,000 workers in the metro area; prosperity, as measured by the regional price parity-adjusted average salary for developers in the area, the growth of wages from 2010-14, and job growth over the same span; talent, based on the number computer science degrees awarded per 10,000 workers, the percentage of of the over-25 population with computer or math degrees, and the replacement rate of IT degree holders in 2014; and the amount of venture capital investment per employee in 2015. Concentration received a 30% weighting with the remaining seven factors being equal at a 10% weighting. The study was conducted by BW Research Partnership for the San Diego Regional Economic Development Corp.

No. 6: Baltimore-Towson, MD Concentration: 13.0 software developers per 1,000 employees

Lazy is a small, Rockville, Md.-based startup that competes in the extremely lucrative healthcare IT market, which is poised to be valued in excess of $228 billion by 2020 according to MarketsandMarkets. Co-founded by Chris Millet, Bobby Jones and Dolly Singh, the small company recently graduated from the newly established Relevant Health business accelerator.

Maryland Governor Larry Hogan visited United Therapeutics headquarters in Silver Spring on Thursday afternoon.

He was joined by Montgomery County Council President Nancy Floreen and Council member Tom Hucker.

QIAGEN N.V. today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of “omics” data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis™, Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.